Seres Therapeutics(MCRB) - 2025 Q4 - Annual Results

Exhibit 99.1 SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side ef ect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026 Seres operational focus on advancing live biotherapeutic programs for inflammatory and immune diseases Company working to create meaningful partnerships with collaborators to suppo ...